fexlamose

Fexlamose is a potent, fast-acting mucolytic drug developed for inhaled pulmonary delivery as a liquid solution by nebulizer or as a dry powder. It is a thiol-modified carbohydrate (thiol-saccharide) that works by cleaving disulfide bridges in mucin polymers, thereby liquefying and breaking down mucus plugs in the airways. This mechanism helps to improve lung function and reduce symptoms in patients with muco-obstructive lung diseases. Fexlamose has demonstrated strong safety and tolerability profiles in Phase 1 clinical studies, with only mild to moderate adverse events reported and no serious adverse events observed. The drug is being developed primarily for chronic obstructive pulmonary disease (COPD) and asthma but may also be considered for other muco-obstructive conditions such as cystic fibrosis and non-CF bronchiectasis. Its proprietary chemistry provides favorable taste and smell characteristics compared to first-generation thiol-based mucolytics like N-acetylcysteine[1][2][3][4].

Brand names

flexlamose

Other names

fexlamose